These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3565033)

  • 1. Scheele lecture. Biopharmaceutical aspects of drug formulation.
    Davis SS
    Acta Pharm Suec; 1986; 23(5):305-14. PubMed ID: 3565033
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biopharmaceutical aspects of parenteral drug formulations].
    Pflegel H
    Pharmazie; 1982 Apr; 37(4):307-18. PubMed ID: 7048344
    [No Abstract]   [Full Text] [Related]  

  • 3. [Formulation of HIV protease inhibitors. Pharmaceutical technology and biopharmaceutic aspects of HIV protease inhibitors].
    Leopold CS
    Pharm Unserer Zeit; 2001; 30(3):234-9. PubMed ID: 11400673
    [No Abstract]   [Full Text] [Related]  

  • 4. Biopharmaceutical benchmarks--2003.
    Walsh G
    Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biopharmacy--what is that?].
    Wulff O
    Ugeskr Laeger; 1973 Jul; 135(28):1477-9. PubMed ID: 4757144
    [No Abstract]   [Full Text] [Related]  

  • 6. Aspects of current parenteral formulation.
    Scheindlin S
    Bull Parenter Drug Assoc; 1970; 24(1):31-9. PubMed ID: 5415610
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biopharmaceutics and drug formulation].
    Riccieri FM
    Ann Ist Super Sanita; 1982; 18(3):541-6. PubMed ID: 7187842
    [No Abstract]   [Full Text] [Related]  

  • 8. Formulation of diazepam containing rectal suppositories and experiences of their biopharmaceutical study.
    Regdon G; Bácskay I; Kata M; Selmeczi B; Szikszay M; Sánta A; Bálint GS
    Pharmazie; 1994 May; 49(5):346-9. PubMed ID: 8016180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of pharmaceutical formulation for dermatological preparations.
    Ross G
    Boll Chim Farm; 1981 Aug; 120(8):437-57. PubMed ID: 7317170
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug formulation and biologic availability.
    Poole JW
    Semin Drug Treat; 1971 Sep; 1(2):148-76. PubMed ID: 5153883
    [No Abstract]   [Full Text] [Related]  

  • 11. Nanosizing--oral formulation development and biopharmaceutical evaluation.
    Kesisoglou F; Panmai S; Wu Y
    Adv Drug Deliv Rev; 2007 Jul; 59(7):631-44. PubMed ID: 17601629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.
    Maas J; Kamm W; Hauck G
    Eur J Pharm Biopharm; 2007 Apr; 66(1):1-10. PubMed ID: 17123801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biopharmaceutical aspects of pharmaceutical technology].
    Thoma K
    Pharmazie; 1981 Mar; 36(3):185-93. PubMed ID: 7279982
    [No Abstract]   [Full Text] [Related]  

  • 14. The Resotest Apparatus. A universally applicable biopharmaceutical experimental tool.
    Koch HP
    Methods Find Exp Clin Pharmacol; 1980 Apr; 2(2):97-102. PubMed ID: 7339334
    [No Abstract]   [Full Text] [Related]  

  • 15. Mixing in process vessels used in biopharmaceutical manufacturing.
    Ram K; Vickroy TB; Lamb KA; Slater NK; Dennis JS; Duffy LE
    Biotechnol Prog; 2000; 16(2):244-7. PubMed ID: 10753450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of certain tablet formulation factors on the antimicrobial activity of tetracycline hydrochloride and chloramphenicol. 2. Effect of disintegrants.
    Asker A; el-Nakeeb M; Motawi M; el-Gindy N
    Pharmazie; 1973 Jul; 28(7):474-6. PubMed ID: 4767500
    [No Abstract]   [Full Text] [Related]  

  • 17. [Significance of biopharmaceutics for practical drug therapy].
    Dettli L
    Helv Med Acta Suppl; 1970 Jun; ():Suppl 50:57-63. PubMed ID: 5288609
    [No Abstract]   [Full Text] [Related]  

  • 18. Voices in
    Moseson DE
    Mol Pharm; 2023 Aug; 20(8):3696-3697. PubMed ID: 37506188
    [No Abstract]   [Full Text] [Related]  

  • 19. Proceedings: The effect of formulation on the availability of sulphadiazine.
    Garnham JC; Raymond K; Shotton E; Turner P
    J Pharm Pharmacol; 1973 Dec; 25():Suppl:151P-152. PubMed ID: 4150557
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biopharmaceutical evaluation of preparations intended for the parenteral route].
    Aiache JM; Aiache S
    Boll Chim Farm; 1983 May; 122(5):213-28. PubMed ID: 6357232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.